XML 53 R19.htm IDEA: XBRL DOCUMENT
v3.22.1

Net Loss Per Share Attributable to Ordinary Shareholders | 12 Months Ended
--- | ---
Dec. 31, 2021
Earnings Per Share [Abstract] |
Net Loss Per Share Attributable to Ordinary Shareholders | Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive. The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:
|  | Year ended |  |  | Year ended |
|  | December 31 |  |  | December 31 |
|  | 2021 |  |  | 2020 |
|  | In USD thousands, except share and per share data |
Numerator: |  |  |  |  |  |  |  |
Net loss |  |  | 12,478 |  |  |  | 5,951 |
Denominator: |  |  |  |  |  |  |  |
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted |  |  | 207,468,650 |  |  |  | 136,755,498 |
Net loss per share attributable to ordinary shareholders, basic and diluted |  |  | 0.060 |  |  |  | 0.044 |
F - 24
Chemomab Therapeutics Ltd. and its subsidiaries
Notes to the Financial Statements as at December 31, 2021
Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders (cont'd) The potential number of weighted-average ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:
|  | Year ended |  |  | Year ended |
|  | December 31 |  |  | December 31 |
|  | 2021 |  |  | 2020 |
|  | Number of shares |
Outstanding options to purchase ordinary shares |  |  | 27,003,260 |  |  |  | 10,455,580 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration